Phase II Maraviroc for GVHD Prevention

Inclusion Criteria

• •Patients ≥18 years of age with a hematologic malignancy other than aplastic anemia or primary myelofibrosis, scheduled to undergo RIC allogeneic SCT with a peripheral blood stem cell graft from an unrelated donor, using Flu/Bu conditioning and Tac/MTX GVHD prophylaxis. The following diagnoses are included:
• •* Acute leukemia - AML, ALL or acute biphenotypic leukemia. Patients will have documentation of complete remission within 6 weeks prior to their transplant. Complete remission is defined as \<5% blasts on a bone marrow biopsy and absence of any known extramedullary disease.
• •* Chronic myelogenous leukemia in any stage, but with documentation of \<5% blasts on a bone marrow biopsy within 6 weeks prior to transplant.
• •* Myelodysplastic syndrome of any subtype, but with documentation of \<5% blasts on a bone marrow biopsy within 6 weeks prior to transplant.
• •* Myeloproliferative disorders other than primary myelofibrosis.
• •* Lymphoma - All types of lymphoma are eligible.
• •* CLL and PLL.
• •Patients who meet institutional eligibility criteria for allogeneic SCT:
• •* Renal function: Serum creatinine ≤2.
• •* Hepatic function: Baseline direct bilirubin, ALT or AST lower than three times the upper limit of normal.
• •* Pulmonary disease: FVC or FEV1 ≥ 40% predicted.
• •* Cardiac ejection fraction ≥ 40%.
• •Availability of an unrelated donor, identified and screened by the NMDP. The donor will have at least 7/8 HLA-A, -B, -C and -DRB1 matching by high resolution molecular typing and will meet NMDP eligibility criteria to serve as a peripheral blood stem-cell donor.
• •Karnofsky score ≥ 70% at the time of screening.
• •Capacity to understand and sign the study informed consent form.
• •Negative pregnancy test. Women of childbearing potential (not having had a hysterectomy, a bilateral oophorectomy or bilateral tubal ligation, or be post-menopausal with a total cessation of menses of \> 1 year) must agree to use documented reliable method(s) of contraception. Men should agree to use condoms during the study period.
• •* Co-enrollment in other clinical trials that do not include experimental GVHD therapies is allowed.